Washington State University Reactor

Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™

Retrieved on: 
Wednesday, September 14, 2022
Half-life, Patent Cooperation Treaty, Temperature, University, Safety, Radiation, Engineering, Human, PCT, Solvent, Sale, FDA, Food, Gel, Sarcoma, Neoplasm, Name, OTCQB, Company, Washington State University Reactor, Private Securities Litigation Reform Act, Confusion, Forward-looking statement, United States patent law, Hydrogel, Brachytherapy, Technology, Quality management system, Patent, Vivos, Tissue, Method, Veterinary medicine, Skin cancer, Injection (medicine), GLOBE, Food and Drug Administration, Marketing, Animal, Structured Product Labeling, FDA Center for Devices and Radiological Health, GMP, 3D printing, Risk management, Medical imaging, Pharmaceutical industry

Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component.

Key Points: 
  • Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component.
  • As part of this process, we just filed a patent application on the hydrogel component, while keeping the production refinements as important proprietary intellectual property.
  • This filing was on the heels of another milestone for Vivos, as the US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, US Patent Application Serial No: 16-459,466.
  • Our new particle patent and our hydrogel component patent filing are significant achievements consistent with our objective for strong intellectual property protection on both of our key components.

Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy

Retrieved on: 
Tuesday, August 16, 2022
FDA, Sarcoma, Forward-looking statement, Name, GLOBE, Neoplasm, Technology, Private Securities Litigation Reform Act, Half-life, Washington State University Reactor, Sale, Tissue, Urine, Hydrogel, Method, Brachytherapy, University, Marketing, Engineering, Company, Gel, Structured Product Labeling, Radiation, Safety, FDA Center for Devices and Radiological Health, Feces, OTCQB, Confusion, Food and Drug Administration, Human, Animal, Vivos, Veterinary medicine, Food, Temperature, Horse, Pharmaceutical industry, Medical imaging

Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet therapy for treating solid tumors in horses.

Key Points: 
  • Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet therapy for treating solid tumors in horses.
  • Dr. Korenko stated, We are in active discussions related to opening additional equine clinics and are excited about offering Isopet as a game changing treatment option for treating solid tumors in horses.
  • Vivos Inc. has developed an Yttrium-90 based injectable Precision Radionuclide Therapy brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet to University animal hospitals and private veterinary clinics.

Vivos Inc. Provides Intellectual Property Protection Update

Retrieved on: 
Thursday, May 12, 2022
Structured Product Labeling, Engineering, FDA Center for Devices and Radiological Health, Company, Neoplasm, Private Securities Litigation Reform Act, Radiation, Food and Drug Administration, Food, PCT, Confusion, Patent Cooperation Treaty, Veterinary medicine, Half-life, Marketing, Method, Patent, FDA, Gel, Hydrogel, Forward-looking statement, Human, University, Tissue, Safety, Technology, Name, Sale, Temperature, Brachytherapy, Sarcoma, Vivos, Animal, GLOBE, OTCQB, Washington State University Reactor, 3D printing, Medical imaging, Pharmaceutical industry

Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts.

Key Points: 
  • Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts.
  • This year we also filed a provisional patent number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components.
  • This week we filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).

Vivos Inc Implements Multiple Patient IsoPet® Therapy Day

Retrieved on: 
Thursday, April 21, 2022
Amputation, Gel, Confusion, University, Food and Drug Administration, FedEx, Marketing, Johns Hopkins University, Half-life, Food, Human, Private Securities Litigation Reform Act, Vivos, GLOBE, Sale, Patient, Engineering, Tissue, Neoplasm, FDA Center for Devices and Radiological Health, Structured Product Labeling, Technology, Temperature, Company, OTCQB, Method, Radiation, Forward-looking statement, Animal, Policy, Safety, Veterinary medicine, Hydrogel, Name, FDA, Washington State University Reactor, Brachytherapy, Sarcoma, Pharmaceutical industry, Medical imaging

The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.

Key Points: 
  • The Isopet treatments went smoothly from our single production run delivered via overnight delivery directly to the clinic.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).
  • Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet to University animal hospitals and private veterinary clinics.

Vivos Inc. Enhances its Intellectual Property Protection

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Half-life, Human, Method, Washington State University Reactor, Neoplasm, Animal, Name, Brachytherapy, Food and Drug Administration, Hydrogel, University, Radiation, Tissue, Gel, Company, Sale, Private Securities Litigation Reform Act, Safety, Veterinary medicine, Temperature, Food, Structured Product Labeling, FDA, Sarcoma, OTCQB, Forward-looking statement, Marketing, Union, Patent, Vivos, Technology, Engineering, Confusion, FDA Center for Devices and Radiological Health, Medical imaging, Pharmaceutical industry

Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries.

Key Points: 
  • Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries.
  • In closing Dr. Korenko stated, Intellectual property protect is always a priority and over time becomes increasingly important.
  • Our strategic plan is to use our intellectual property as a foundation for our exclusive licensing strategy in several regions in the world.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).

Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™

Retrieved on: 
Thursday, December 2, 2021
Tissue, Private Securities Litigation Reform Act, Mayo Clinic, IDE, Sale, Washington, Half-life, Safety, Missouri, Technology, Hydrogel, Temperature, Forward-looking statement, Company, Neoplasm, Confusion, Sarcoma, Investigator's brochure, Brachytherapy, Human, University, Thyroid cancer, Review, Animal, Physician, Vivos, GLOBE, Marketing, OTCQB, Food and Drug Administration, Investigational device exemption, FDA, Radiation, Gel, Washington State University Reactor, Name, Engineering, Veterinary medicine, FDA Center for Devices and Radiological Health, Skin cancer, Method, Structured Product Labeling, Food, Mayo, Medical device, Pharmaceutical industry, Medical imaging

The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing.

Key Points: 
  • The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing.
  • This was the first time the Mayo Clinic Doctors met with the FDA regarding RadioGel.
  • They were able to communicate the unmet medical need that RadioGel could address and successfully fielded several key questions from the FDA reviewers.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).

Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®

Retrieved on: 
Monday, November 22, 2021
Tissue, Private Securities Litigation Reform Act, Sale, Washington, Safety, Half-life, Cancer, Missouri, Technology, Publication, Hydrogel, Temperature, Company, Neoplasm, Forward-looking statement, Awareness, Confusion, Sarcoma, Brachytherapy, Human, University, Food, Animal, Johns Hopkins, Vivos, GLOBE, Marketing, OTCQB, FDA, Food and Drug Administration, Radiation, Gel, Washington State University Reactor, Name, Johns Hopkins University, Engineering, Veterinary medicine, FDA Center for Devices and Radiological Health, Skin cancer, Certification, Method, Structured Product Labeling, Pharmaceutical industry, Medical imaging

Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet regional clinic.

Key Points: 
  • Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet regional clinic.
  • Dr. Mike Korenko stated, Our business plan is to establish new IsoPet regional centers across the United States and then internationally.
  • John Hopkins University has an excellent reputation and we are excited to add Johns Hopkins as an Isopet regional clinic.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).

Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy

Retrieved on: 
Monday, October 18, 2021
Vivos, Food and Drug Administration, Human, Sarcoma, Technology, Name, OTCQB, Certification, Private Securities Litigation Reform Act, Washington, Washington State University Reactor, Radiation, Method, Neoplasm, Confusion, Tissue, Engineering, PETS, Half-life, Brain, Marketing, Gel, FDA, Veterinary medicine, Temperature, Brachytherapy, Surgeon, Food, GLOBE, Hydrogel, University, Company, Forward-looking statement, FDA Center for Devices and Radiological Health, Structured Product Labeling, Skin cancer, Bladder cancer, Sale, Safety, Animal, Missouri, Pharmaceutical industry, Medical imaging

Vivos Inc is currently working on obtaining the radioactive material handling license and on completing their certification training.

Key Points: 
  • Vivos Inc is currently working on obtaining the radioactive material handling license and on completing their certification training.
  • Dr. Mike Korenko stated, After licensing and certification, this will be our first east coast regional center and it is near a major population center.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).
  • Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet to University animal hospitals and private veterinary clinics.

Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics

Retrieved on: 
Wednesday, September 22, 2021
Veterinary medicine, Temperature, Food, Neoplasm, OTCQB, Animal, Washington State University Reactor, Brachytherapy, Radiation, FDA Center for Devices and Radiological Health, Sale, Half-life, FDA, Certification, Washington, Food and Drug Administration, Structured Product Labeling, University, Company, Vivos, Missouri, Gel, Confusion, Sarcoma, Technology, Human, Tissue, Safety, Hydrogel, Name, GLOBE, Medical device, Medical imaging

Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics.

Key Points: 
  • Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics.
  • The modules are now on the FX Masse website with a separate unique UR web browser for Vivos Inc.
  • A new clinic can complete each module at their convenience as a pre-cursor to the hands-on certification training sessions.
  • We needed to create an efficient and consistent process to initiate the establishment of regional clinics for IsoPet therapy.

Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™

Retrieved on: 
Monday, September 20, 2021
Food, Temperature, Veterinary medicine, Neoplasm, OTCQB, Animal, Washington State University Reactor, Brachytherapy, Radiation, Food and Drug Administration, Review, Investigator's brochure, Efficiency, FDA Center for Devices and Radiological Health, Sale, Half-life, FDA, IDE, Washington, Structured Product Labeling, University, Company, Vivos, Communication, Missouri, Gel, Confusion, Sarcoma, Technology, Human, Tissue, Safety, Hydrogel, Name, GLOBE, Pharmaceutical industry, Medical imaging

The FDA recommended this path to facilitate enhanced ongoing communication with Vivos and to increase the efficiency of the review process.

Key Points: 
  • The FDA recommended this path to facilitate enhanced ongoing communication with Vivos and to increase the efficiency of the review process.
  • This filing is an important milestone for Vivos and reflects the efforts of numerous parties.
  • In particular, we are pleased that this IDE filing included the Mayo Clinic Clinical Trial Protocol for Radiogel, which is currently being reviewed by Mayos Independent Review Team.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet) and in humans (RadioGel).